Why Should It Be Remarkable That a Company Solved a Real Problem While Making Profit? What Gilead and Merck’s HIV Pill Reveals About Institutional Choice
Phase 3 data shows that Gilead and Merck’s weekly HIV pill works, representing a major advance in treatment adherence and patient outcomes. This should be unremarkable news. A pharmaceutical company developed an innovation that solves a genuine medical problem. Patients benefit. The company profits. This is how the system is supposed to work. But it’s remarkable…